PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Enalapril

Drugs in development · updated 30 October 2026

Enalapril: clinical trials and development status

Other names and codes: Epaned, Aqumeldi

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 15 November 2023

As of 30 October 2026 Enalapril is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 7 diseases. The most advanced phase is III.

3Active trials
IIIMost advanced phase
7Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Enalapril and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Arterial hypertensionIII1NCT07222852
Hypertension, Pregnancy-InducedIII1NCT07222852
Pre-eclampsiaIII1NCT07222852
ToxemiaIII1NCT07222852
Membranoproliferative glomerulonephritisII1NCT04183101
PainII1NCT06788314
Vascular malformationII1NCT06788314

Everything on Enalapril

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch